Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 26031-26040 Newer>

The Motley Fool September 11, 2007 Brian Orelli	A Waiting Game for Aspreva It will be three years before Aspreva Pharmaceuticals and partner Roche evaluate results for a treatment for lupus. If and when the drug is approved, it will have to compete with a whole host of other drugs currently in trials. Investors take note.
The Motley Fool September 11, 2007 Toby Shute	Energy Jargon, Demystified: "Upstream" With all the recent buzz surrounding the energy sector, it's good to understand the industry jargon. "Upstream" refers to the companies that find and produce hydrocarbons. Is it time to add some upstream exposure to your portfolio?
The Motley Fool September 11, 2007 David Lee Smith	Time to Re-Oil Your Portfolio Despite the world's rapt attention to its meetings, OPEC gatherings mean very little. Most of the OPEC nations are already producing at pretty close to their all-out capacity. Investors should take note, and tend to the energy portions of their portfolios.
The Motley Fool September 11, 2007 Brian Lawler	Score One for Pharmasset Shares of Pharmasset were up after the company announced impressive results for its Hepatitis C virus drug candidate R7128. Investors should continue to watch closely.
The Motley Fool September 11, 2007 Alyce Lomax	McDonald's Hot August The fast-food giant shows little sign of slowing. With a 39% share price rise over the past year, and a willingness to evolve and take the company into the future, investors may want to consider McDonald's as a long-term investment.
The Motley Fool September 11, 2007 Tom Taulli	Virtusa's Platforming Shoes The information technology consultant Virtusa continues to grow, for now. Fiscal Q1 results show a healthy increase in revenues and operating income, but the India based company is beginning to feel the pain of the rising rupee and competition.
The Motley Fool September 11, 2007 Brian Lawler	Where Momenta Stands Momenta Pharmaceuticals updates investors as to the status of drugs in its pipeline. Until the FDA makes up its mind on its lead drug, an anticoagulant, it's anyone's guess as to what the value of the pipeline is. Investors should take note.
The Motley Fool September 11, 2007 Rich Smith	Smith & Wesson Aims Higher With continued strong sales growth and higher-than-expected margins, the arms maker upped guidance for the rest of the year. Investors take note.
The Motley Fool September 11, 2007 Rimmy Malhotra	Opportunities in Outsourcing Investors, take a look at some outsourcing, regulatory, and compliance companies that may look boring, but often reward well.
The Motley Fool September 11, 2007 Sham Gad	Short-Selling Will Short-Change You Short-selling is the process of selling borrowed shares with the hope of buying them back at a lower price. The odds are stacked against you.
<Older 26031-26040 Newer> Return to current articles.